1. Circulating and locally formed Angiotensin II regulates the cerebral circulation through stimulation of AT 1 receptors located in cerebrovascular endothelial cells and in brain centers controlling cerebrovascular flow.
8. These results strongly suggest that inhibition of AT 1 receptors should be considered as a preventive therapeutic measure to protect the brain from ischemia, and as a possible novel therapy of inflammatory conditions of the brain.
INTRODUCTION
Angiotensin II (Ang II), initially described as a peripheral circulating hormone regulating systemic blood pressure and fluid homeostasis, was later recognized as a brain neuromodulator inducing fluid and salt intake and blood pressure increase through stimulation of its physiological receptors, the AT 1 receptor type (Saavedra, 2005) . There are two closely integrated central Ang II systems, one responding to Ang II generated in the brain and stimulating receptors inside the blood brain barrier (Saavedra, 1992) and another with Ang II receptors in circumventricular organs and in cerebrovascular endothelial and smooth muscle cells ( Fig. 1) (Zhou et al., 2005) , responding to circulating Ang II of peripheral origin, and/or to locally generated Ang II (Saavedra, 2005) . AT 1 receptors located in the cerebrovascular endothelium and in specific brain areas participate in the regulation of the cerebrovascular circulation (Saavedra, 2005) .
CEREBROVASCULAR AUTOREGULATION
One important characteristic of the cerebral circulation is the capacity to adapt to variations in systemic or local blood pressure by regulating the degree of vasoconstriction and vasodilatation of the cerebral arteries, maintaining a constant blood flow to the brain. Under normal conditions, decreases in perfusion pressure result in Zhou et al. (2005). vasodilatation, while increases in pressure produce vasoconstriction, to maintain a constant overall blood flow to the brain, a system of cerebrovascular autoregulation (Fig. 2) .
CEREBROVASCULAR AUTOREGULATION IN HYPERTENSION
In established hypertension there is pathological growth and remodeling of the cerebral circulation, with increased medial thickness, collagen formation, cell growth and number and reduction of arterial lumen and vasoconstriction (Fig. 3) . In spontaneously hypertensive rats (SHR) these alterations reduce cerebrovascular compliance, the capacity of the arteries to dilate when faced with a reduction of pressure and blood flow. There is a shift of the autoregulatory curve to the right, in the direction of higher blood pressures (Nishimura et al., 2000b) . The practical consequence is that, in hypertension, because the capacity for vasodilatation is reduced, the cerebral blood flow is more vulnerable to decreased perfusion pressure (Fig. 2) . Alterations in endothelial function and fibrinolysis lead to arteriosclerosis and further reduction of arterial caliber. For these reasons ischemia and stroke are frequent in hypertension (Ross, 1993; Harrison, 1997) .
Hypertension increases the frequency of sudden reductions of blood flow in principal arteries such as the medial cerebral artery. Collateral arteries attempt Fig. 2 . Cerebrovascular autoregulation. Cerebral blood flow is maintained constant over a range of systemic blood pressures by changes in the degree of vasodilatation and vasoconstriction of cerebral arterioles. During hypertension, decreased cerebrovascular compliance shifts the autoregulatory curve to the right, in the direction of higher blood pressures (grey arrow). This explains the vulnerability to reduction in perfusion pressure during hypertension. Brain arteries are less able to dilate and this results in reductions of blood flow to the brain, ischemia and neuronal injury. AT 1 blockade improves cerebrovascular compliance reducing the shift to the right in the autoregulatory curve (black arrow) and the risk of ischemia. to dilate and maintain blood flow to the region affected. The degree of preservation of blood flow by the collateral circulation determines the size of the ischemic area and neuronal injury, and therefore, the clinical consequences of the ischemic episode. Strokes following occlusion of cerebral arteries are characterized by a development of a necrotic core (Fig. 3) , the area receiving most of its flow from the blocked artery, surrounded by a zone of "penumbra" where neuronal survival depends on the preservation of the collateral circulation. Below a certain threshold of blood flow there is permanent neuronal injury and death . The response of the collateral circulation to ischemia is compromised in hypertension because of the reduced arterial compliance as explained previously and for these reasons strokes are more frequent and more severe in hypertensive subjects. 
CEREBROVASCULAR ANGIOTENSINERGIC OVERDRIVE IN HYPERTENSION AND ITS CONSEQUENCES
The activity of the brain Ang II system is enhanced in SHR (Saavedra, 1992 ) and these animals express higher numbers of AT 1 receptors in the cerebral vasculature, (Ando et al., 2004) . The result of excess AT 1 receptor stimulation is an important cause of cerebrovascular vasoconstriction, increased pathological growth and decreased cerebrovascular compliance in hypertension (Nishimura et al., 2000b) .
In addition, the cerebral vasculature of hypertensive animals exhibits signs of inflammation and endothelial dysfunction, including macrophage attachment and infiltration (Ando et al., 2004) (Fig. 4) , enhanced expression of inflammatory markers such as ICAM-1 and TNF-α and increased heat shock protein (HSP) expression in the microvessel endothelium (Zhou et al., 2005) (Fig. 5) . Heat shock proteins induce proinflammatory responses including secretion of adhesion molecules and cytokines (Asea et al., 2000; Wallin et al., 2002) , and the induction of HSPs previously primed by inflammation accelerates cell death by apoptosis (Buchman et al., 1993; Abello and Buchman, 1994) . This is consistent with the observation that long-term administration of Ang II induces expression of HSPs by mechanisms unrelated to hypertension and dependent on AT 1 activation (Ishizaka et al., 2002) . Endothelial dysfunction and vascular inflammation enhance vulnerability to hypertensive brain damage and are major risk factors for brain ischemia and stroke (Amenta et al., 2003; Lawes et al., 2004) . Vascular inflammation is at least partially due to excess Ang II formation (Pastore et al., 1999; Pueyo et al., 2000; Ruiz-Ortega et al., 2000; Touyz, 2003) and to increased AT 1 receptor stimulation (Ando et al., 2004; Zhou et al., 2005) .
There are prominent alterations in nitric oxide (NO) production in the cerebral vasculature in hypertension. The complex role of nitric oxide (NO) production in cerebral arteries is linked to both vasodilatation and to inflammation, and there is a well-known association between the Ang II and NO systems (Briones et al., 2002) . Nitric oxide synthase (NOS) isoenzymes are selectively localized in cerebral vessels, Fig. 5 . Regulation of heat shock protein transcripts in microvessels from SHR and WKY rats and effects of sustained AT 1 receptor blockade. Expression of transcripts for heat shock proteins (HSP) 70, 60 and 90 was studied with the use of Affymetrix GeneChip U34A arrays (Zhou et al., 2005) . Note increased expression of HSP 70, HSP 60 and HSP 90 in SHR when compared to WKY rats, and decreased expression of HSP 70 after candesartan treatment (modified from Zhou et al., 2005) .
endothelial NOS (eNOS) located in the endothelium and inducible NOS (iNOS) in the adventitia. In hypertension, there is decreased eNOS and increased iNOS expression, and this alteration of the eNOS/iNOS ratio favors inflammation and reduces vasodilatation (Yamakawa et al., 2003) . AT 1 receptor stimulation decreases eNOS expression (Yamakawa et al., 2003) . NOS inhibition promotes ICAM-1 expression (Luvara et al., 1998) and macrophage infiltration (Luvara et al., 1998; Usui et al., 2000) and adherence (Kiarash et al., 2001; Ando et al., 2004) and increases production of interleukin-1β, (Bauer et al., 1995) a proinflammatory cytokine that upregulates ICAM-1 expression (McCarron et al., 1994; Galea et al., 1998; Staykova et al., 2000; Schoning et al., 2002) . These alterations explain the decreased vasodilatation and enhanced formation of reactive oxygen species correlated with arterial vasoconstriction and inflammation.
THERAPEUTIC MEASURES FOR THE PREVENTION OF STROKE
Inhibition of the mechanisms leading to decreased vascular compliance and inflammation is one of the principal strategies for the prevention of brain ischemia during hypertension. A sustained inhibition of peripheral and central Ang II AT 1 receptors with peripheral administration of candesartan, an AT 1 receptor blocker (ARB) with access to the brain (Nishimura et al., 2000a) normalizes cerebrovascular compliance in SHR, correcting the shift to the right characteristic of cerebrovascular autoregulation during hypertension (Nishimura et al., 2000b) (Fig. 2) . The practical consequence of the correction of the autoregulatory curve is that after blockade of a major cerebral artery, collateral arteries recover their capacity to dilate, maintaining the blood flow above the required threshold in the periphery of the lesion, the penumbra zone, and reducing the area of ischemia and neuronal injury (Fig. 3 ).
There is a good correlation between the area of blood flow below the required protective threshold and the area of neuronal injury and death, both significantly reduced by AT 1 receptor blockade . The underlying mechanisms of the ARB effect include a blockade of the vasoconstrictive and pro-growth effects of Ang II (Fig. 3) .
The inflammatory response in cerebral microvessels of SHR depends on Ang II stimulation (Takemori et al., 2000; Suzuki et al., 2001; Ando et al., 2004) and can be suppressed by blockade of its AT 1 receptors. Sustained treatment with the ARB reverses the alterations in eNOS expression, (Yamakawa et al., 2003) normalizing the eNOS/iNOS ratio. The upregulation of eNOS activity decreases ICAM-1 expression (Scalia et al., 2000; Buras et al., 2000) , the transcription and expression of HSPs and inflammatory markers (Fig. 5) , and prevents macrophage infiltration (Luvara et al., 1998; Usui et al., 2000; Yamakawa et al., 2003; Ando et al., 2004; Zhou et al., 2005) . In this case, reversal of increased HSP and HSF-1 expression by AT 1 receptor blockade might be considered an important mechanism to prevent inflammation, cell damage and apoptosis in brain microvessels, contributing to the end-organ protective effect of Ang II system blockade, as it is the case in peripheral organs (Hilgers et al., 2001; Dandona et al., 2003) . These antiinflammatory effects can explain some of the underlying mechanisms of the decrease in cardiovascular morbidity and mortality, which follow a 7-day course of candesartan when the treatment is administered during the first week after acute stroke (Schrader et al., 2003) .
THE ROLE OF BLOOD PRESSURE DECREASE AND OF THE SELECTIVE INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM
Treatment with candesartan normalizes blood pressure in SHR. It could be argued that protection against ischemia and reduced inflammation is the direct consequence of the blood pressure reduction. However, while both AT 1 receptor blockade or ACE inhibition, which decreases Ang II synthesis, are effective (Nishimura et al., 2000b; Ito et al., 2002) no protection occurs after treatment with β-adrenergic or calcium-blocking agents (Nishimura et al., 2000b; Ito et al., 2002) . In addition, treatment with a low dose of candesartan (0.1 mg/kg) reduced the stroke incidence and urinary protein excretion without affecting the blood pressure (Inada et al., 1997) and in peripheral organs, the antiinflammatory effect of AT 1 antagonists is independent of their effects on blood pressure (Dohi et al., 2003) .
THE ROLE OF AT RECEPTORS
The protective effects of candesartan against brain ischemia may not be only related to direct inhibition of AT 1 receptor stimulation. Treatment with candesartan increases the expression of Ang II AT 2 receptors in brain microvessels (Zhou et al., submitted) (Fig. 6) . AT 2 receptor stimulation, the effects of which have not been completely clarified (Saavedra, 1999) was proposed to result in vasodilatation and inhibition of growth, balancing AT 1 receptor effects (Carey, 2005) . Stimulation of AT 2 receptors enhances endothelial NO formation directly (Hiyoshi et al., 2005) and through stimulation of Bradykinin B 2 receptors in the endothelium (Abadir et al., 2003; Ritter et al., 2003; Batenburg et al., 2004; Fukada et al., 2005) (Fig. 7a) . Stimulation of NO formation is therefore influenced negatively by AT 1 receptor action, and positively by AT 2 receptor (Ritter et al., 2003) and B 2 receptor activity (Fig. 7a) . There are two pharmacological manipulations to decrease AT 1 receptor stimulation, increasing AT 2 and/or B 2 effects on endothelial NO. Inhibition of Ang II formation by inhibition of the Angiotensin Converting Enzyme (ACE) enhances Bradykinin levels by inhibition of its degradation, decreases AT 1 receptor stimulation by decreasing Ang II formation, and the net result is an increase in endothelial NO formation (Chen et al., 2003) (Fig. 7b) . Direct inhibition of AT 1 receptors with ARBs enhances NO formation by removing the inhibitory effect of AT 1 receptor stimulation and increasing AT 2 effects by stimulation of AT 2 receptor expression and increased Ang II formation as a result of decreased inhibitory feed-back of renin production (Fig. 7c) . This explains the protective effects of both ACE inhibitors and ARBs in brain ischemia (Nishimura et al., 2000b) .
The question whether or not AT 2 receptor stimulation plays a significant protective role after brain ischemia has not yet been resolved. There are reports of a possible inhibition of brain ischemia by AT 2 receptor stimulation (Iwai et al., 2004) . This report is based on the finding of enhanced neurological deficits in AT 2 receptor knockout mice following middle cerebral artery occlusion. The authors did not consider that failure of AT 2 receptor transmission results in enhanced brain AT 1 receptor expression (Armando et al., 2002) , a finding which can explain the increased sensitivity of AT 2 receptor knockout mice to ischemia. In addition, blockade of Ang II synthesis with ACE inhibitors should result in a decrease in both AT 1 and AT 2 receptor stimulation. Since protection against brain ischemia occurs not only after AT 1 receptor blockade but also after administration of ACE inhibitors, the logical conclusion is that inhibition of AT 1 receptors is necessary and sufficient for the protection of brain ischemia.
CONCLUSIONS
The reversal of the cerebrovascular pathological growth and inflammation by AT 1 receptor blockade indicates that AT 1 receptor overstimulation is a mayor mechanism leading to increase vulnerability to brain ischemia during hypertension. In addition to their antihypertensive and antigrowth properties, the cerebrovascular antiinflammatory effects of Ang II AT 1 receptor antagonists might be of major importance to protect the brain against neuronal damage due to ischemia. The suppression of inflammation in brain vessels suggests important therapeutic advantages of AT 1 receptor antagonists not only in the prevention of brain ischemia but also in the treatment of inflammatory diseases of the brain.
